NOT MEDICAL ADVICE

AOD-9604

Estimated Market Price
$94.99 $109.99
Based on verified supplier pricing for research-grade compounds
HGH fragment 177-191 | MW: 1815.09 g/mol | Purity: >=97% HPLC | Lyophilized powder, 5mg/vial
How it works

Mimics the fat-burning fragment of natural growth hormone without the muscle-growth or blood sugar side effects. Tells fat cells to release stored energy while blocking new fat storage.

Weight Management

What to Expect
Week 1–2 Lipolytic signaling activated; mild fat mobilization starting. No dramatic change yet; fat mobilization starting silently.
Week 3–4 Measurable reduction in adipose tissue; lipogenesis inhibited. Midsection starting to feel tighter; subtle fat loss.
Week 5–8 Significant fat loss without lean mass reduction observed. Visible fat reduction, especially around the belly.
Week 9–12 Peak lipolytic benefits; body composition measurably improved. Clearly leaner; body composition measurably better.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier
Protocol & Dosage
Typical Dosage 300 mcg SC daily
Administration Subcutaneous injection, Oral (under investigation)
Schedule Once daily, AM on empty stomach or split AM/PM
Protocol Duration 8–12 weeks
Half-Life ~12 minutes
Side Effects & Safety
Tolerability Profile Favorable

Very well tolerated; side effects are rare and mild

Common Side Effects

  • Injection site rednessmost users
  • Mild headachesome users

Less Common

  • Temporary swelling at injection siteoccasional
  • Mild joint discomfortoccasional
  • Mild nauseaoccasional

Discontinue If

  • Severe allergic reaction (rash, swelling, breathing difficulty)
  • Persistent joint pain
  • Unusual swelling

Contraindications

  • Active cancer or tumors
  • Pregnancy or breastfeeding
  • Poorly controlled diabetes

Data note: Received FDA GRAS (Generally Recognized as Safe) status in 2007. One of the better-tolerated peptide fragments.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about AOD-9604
Send us a message

Call us
+1 (518) 327-4392
Business hours
Monday – Friday 9:00 AM – 6:00 PM EST
Saturday 10:00 AM – 2:00 PM EST
Sunday Closed

You can also reach us via or .

How to Apply

1

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

2

Sanitize

Wipe tops of both vials with alcohol swabs

3

Draw

Pull 1–2 mL of BAC water into syringe

4

Add Water

Release water slowly along vial wall, not directly on powder

5

Swirl

Roll between palms until dissolved. Never shake.

6

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for AOD-9604

Also Known As AOD 9604, hGH Fragment 177-191 (modified), Tyr-hGH Frag 176-191
Classification Peptide Fragment · Lipolytic
Sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa)
Molecular Formula C₇₈H₁₂₅N₂₃O₂₃S₂
Molecular Weight 1,815.08 Da
CAS Number 221231-10-3
Half-Life ~12 minutes
Origin Modified C-terminal fragment (176-191) of human growth hormone
Administration Subcutaneous injection, Oral (under investigation)
Status Research · GRAS status (FDA, 2007) for food applications
Mechanism of Action Mimics the fat-burning fragment of natural growth hormone without the muscle-growth or blood sugar side effects. Tells fat cells to release stored energy while blocking new fat storage.
Research Overview AOD-9604 is a modified peptide fragment corresponding to the C-terminal region (amino acids 176-191) of human growth hormone, originally developed by Metabolic Pharmaceuticals Limited in Melbourne, Australia, in collaboration with researchers at Monash University. The compound was born from the observation that the lipolytic (fat-mobilizing) activity of growth hormone resides in a different molecular domain than its growth-promoting and diabetogenic effects - specifically, the C-terminal region containing amino acids 176-191 was identified as the minimal fragment capable of stimulating lipolysis in adipose tissue without activating the growth hormone receptor or affecting IGF-1 levels, insulin sensitivity, or cellular proliferation. AOD-9604 includes a tyrosine residue at the N-terminus (position 176 is naturally a leucine in hGH) to improve stability and activity. The mechanism of action involves stimulation of lipolysis through activation of beta-3-adrenergic receptor pathways and inhibition of lipogenesis (new fat synthesis) through mechanisms that appear to be independent of the classical GH receptor signaling cascade. In obese Zucker rat models, AOD-9604 treatment produced significant reductions in body fat without the hyperglycemia, fluid retention, or acromegalic features associated with growth hormone administration. A Phase IIb clinical trial in obese human subjects, while showing a trend toward greater weight loss compared to placebo, did not reach the predetermined statistical significance threshold, which led to discontinuation of Metabolic Pharmaceuticals' development program. However, the compound subsequently received Generally Recognized as Safe (GRAS) status from the FDA in 2007 as a food ingredient, and research has continued in other directions - notably, studies have shown that AOD-9604 stimulates proteoglycan and collagen synthesis in articular cartilage, leading to its investigation as a potential treatment for osteoarthritis and joint degeneration.

Citations

Published findings on AOD-9604 from peer-reviewed journals.

Research Assistant
Hey, I'm the PepSpace research assistant. Ask me anything about peptides and I'll do my best to help.